UBS/CALL/IDORSIA/10.008/0.125/20.09.24 Stock

Warrant

NIDI6U

CH1250694127

Market Closed - Swiss Exchange 11:20:00 2024-02-23 EST
0.08 ^CHF	+100.00%

Current year

+100.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/10.008/0.125/20.09.24

Latest news about IDORSIA LTD

New data with daridorexant to be presented at SLEEP 2024	06-03	GL
Idorsia Ltd. Announces New Data with Daridorexant to Be Presented at Sleep 2024	06-03	CI
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024	05-31	GL
Idorsia : Invitation to the AGM 2024	05-23	PU

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	NIDI6U
ISIN	CH1250694127
Date issued	2023-04-03
Strike	10.01 CHF
Maturity	2024-09-20 (100 Days)
Parity	8 : 1
Emission price	0.42 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.39 CHF
Lowest since issue	0.02 CHF

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company